<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="acr270045" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACR Open Rheumatol</journal-id><journal-id journal-id-type="iso-abbrev">ACR Open Rheumatol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2578-5745</journal-id><journal-id journal-id-type="publisher-id">ACR2</journal-id><journal-title-group><journal-title>ACR Open Rheumatology</journal-title></journal-title-group><issn pub-type="epub">2578-5745</issn><publisher><publisher-name>Wiley Periodicals, Inc.</publisher-name><publisher-loc>Boston, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40344345</article-id><article-id pub-id-type="pmc">PMC12063068</article-id>
<article-id pub-id-type="doi">10.1002/acr2.70045</article-id><article-id pub-id-type="publisher-id">ACR270045</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Soluble Co&#x02010;Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case&#x02010;Control Study</article-title><alt-title alt-title-type="right-running-head">SIGNIFICANTLY ELEVATED RATES OF SICMS IN PATIENTS WITH PMR AND GCA</alt-title><alt-title alt-title-type="left-running-head">HYSA ET AL</alt-title></title-group><contrib-group><contrib id="acr270045-cr-0001" contrib-type="author"><name><surname>Hysa</surname><given-names>Elvis</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6970-0983</contrib-id><xref rid="acr270045-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acr270045-cr-0002" contrib-type="author" corresp="yes"><name><surname>Camellino</surname><given-names>Dario</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6384-6458</contrib-id><xref rid="acr270045-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>dario.camellino@edu.unige.it</email></address></contrib><contrib id="acr270045-cr-0003" contrib-type="author"><name><surname>Dejaco</surname><given-names>Christian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0173-0668</contrib-id><xref rid="acr270045-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acr270045-cr-0004" contrib-type="author"><name><surname>Bauckneht</surname><given-names>Matteo</given-names></name><xref rid="acr270045-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acr270045-cr-0005" contrib-type="author"><name><surname>Pesce</surname><given-names>Giampaola</given-names></name><xref rid="acr270045-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acr270045-cr-0006" contrib-type="author"><name><surname>Morbelli</surname><given-names>Silvia</given-names></name><xref rid="acr270045-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="acr270045-cr-0007" contrib-type="author"><name><surname>Bagnasco</surname><given-names>Marcello</given-names></name><xref rid="acr270045-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="acr270045-cr-0008" contrib-type="author"><name><surname>Cutolo</surname><given-names>Maurizio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5396-0932</contrib-id><xref rid="acr270045-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="acr270045-cr-0009" contrib-type="author"><name><surname>Matteson</surname><given-names>Eric L.</given-names></name><xref rid="acr270045-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="acr270045-cr-0010" contrib-type="author"><name><surname>Cimmino</surname><given-names>Marco A.</given-names></name><xref rid="acr270045-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="acr270045-cr-0011" contrib-type="author"><name><surname>Saverino</surname><given-names>Daniele</given-names></name><xref rid="acr270045-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="acr270045-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Department of Experimental Medicine (DIMES), University of Genova</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>DIMES, University of Genova, Division of Rheumatology, &#x0201c;La Colletta&#x0201d; Hospital, Local Health Trust 3</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, and Department of Rheumatology, Hospital of Brunico (SABES&#x02010;ASDAA), Department of Rheumatology, Teaching Hospital of the Paracelsus Medical University</institution>
<city>Brunico</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Department of Health Sciences, University of Genova</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Department of Internal Medicine, Immunology Unit, University of Genova, Diagnostic Laboratory of Autoimmunology, IRCSS Ospedale Policlinico San Martino</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Nuclear Medicine Unit, Department of Medical Sciences</named-content>
<institution>University of Turin</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine and Medical Specialties</named-content>
<institution>University of Genova</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine</named-content>
<institution>University of Genova, IRCSS Ospedale Policlinico San Martino</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Mayo Clinic College of Medicine and Science</institution>
<city>Rochester</city>
<named-content content-type="country-part">Minnesota</named-content>
</aff><aff id="acr270045-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine</named-content>
<institution>University of Genova</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="acr270045-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">DIMES, University of Genova, Diagnostic Laboratory of Autoimmunology</named-content>
<institution>IRCSS Ospedale Policlinico San Martino</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
Address correspondence via email to Dario Camellino: MD, PhD, MHA, at <email>dario.camellino@edu.unige.it</email>.<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>7</volume><issue seq="18">5</issue><issue-id pub-id-type="doi">10.1002/acr2.v7.5</issue-id><elocation-id>e70045</elocation-id><history>
<date date-type="rev-recd"><day>09</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>06</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 American College of Rheumatology--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">ACR Open Rheumatology</italic> published by Wiley Periodicals LLC on behalf of American College of Rheumatology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACR2-7-e70045.pdf"/><abstract><sec id="acr270045-sec-0001"><title>Objective</title><p>A dysregulated immune response is involved in the pathogenesis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). These diseases have been reported as immune&#x02010;related adverse events in patients with cancer treated with immune checkpoints inhibitors. In this cross&#x02010;sectional study, the relationship between soluble immune checkpoint molecules (sICMs) and clinical/imaging features of PMR and GCA was investigated.</p></sec><sec id="acr270045-sec-0002"><title>Methods</title><p>Consecutive patients with PMR diagnosed according to the criteria by Bird et al were compared with age&#x02010; and sex&#x02010;matched healthy controls. Patients with PMR and overlapping GCA had to also satisfy the 1990 ACR classification criteria for GCA. All patients underwent standardized clinical, laboratory examination, and <sup>18</sup>F&#x02010;fluorodeoxyglucose positron emission tomography/computed tomography scans. The sICM anticytotoxic T Ly&#x02010;4, the programmed cell death protein 1 (PD&#x02010;1), and PD&#x02010;1 ligands PD&#x02010;L1 and PD&#x02010;L2 were measured by enzyme&#x02010;linked immunosorbent assay.</p></sec><sec id="acr270045-sec-0003"><title>Results</title><p>Forty patients (80% women, mean age 76 years, and mean disease duration 88 days) were assessed. Of these, 30 had isolated PMR and 10 had PMR with GCA. Patients showed significantly higher concentrations of all sICMs compared with controls (<italic toggle="no">P</italic> &#x0003c; 0.001). Conditional logistic regression revealed the strong discriminative capacity of these molecules between patients and healthy controls, with PD&#x02010;1 showing complete separation among groups (effect size = 0.78) and PD&#x02010;L1 (odds ratio [OR] 134.33, <italic toggle="no">P</italic> &#x0003c; 0.001) and PD&#x02010;L2 (OR 63.00, <italic toggle="no">P</italic> &#x0003c; 0.001) demonstrating the strongest ability to distinguish patients from controls. Correlations between sICM levels and clinical features were generally weak or absent, with no significant differences based on disease phenotype or glucocorticoid exposure. Results were similar in glucocorticoid&#x02010;naive patients.</p></sec><sec id="acr270045-sec-0004"><title>Conclusion</title><p>sICMs are significantly elevated in PMR and GCA and strongly differentiate patients from healthy controls. Although they do not correlate with clinical or imaging features, their consistent elevation in active disease might suggest a complex interplay between innate and adaptive immunity.</p><p>
<boxed-text position="anchor" content-type="graphic"><graphic xlink:href="ACR2-7-e70045-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></sec></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="acr270045-blkfxd-0102"><graphic xlink:href="ACR2-7-e70045-g001.jpg" position="anchor" id="jats-graphic-3"/></boxed-text>
</p></abstract><counts><fig-count count="5"/><table-count count="4"/><page-count count="10"/><word-count count="7500"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acr270045-ntgp-0001"><fn id="acr270045-note-0001"><p>
<sup>1</sup>Elvis Hysa, MD: Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy; <sup>2</sup>Dario Camellino, MD, PhD, MHA: DIMES, University of Genova, Division of Rheumatology, &#x0201c;La Colletta&#x0201d; Hospital, Local Health Trust 3, Genova, Italy; <sup>3</sup>Christian Dejaco, MD, PhD, MBA: Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, and Department of Rheumatology, Hospital of Brunico (SABES&#x02010;ASDAA), Department of Rheumatology, Teaching Hospital of the Paracelsus Medical University, Brunico, Italy; <sup>4</sup>Matteo Bauckneht, MD, PhD: Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Department of Health Sciences, University of Genova, Genova, Italy; <sup>5</sup>Giampaola Pesce, PhD: Department of Internal Medicine, Immunology Unit, University of Genova, Diagnostic Laboratory of Autoimmunology, IRCSS Ospedale Policlinico San Martino, Genova, Italy; <sup>6</sup>Silvia Morbelli, MD, PhD: Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, Italy; <sup>7</sup>Marcello Bagnasco, MD: Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy; <sup>8</sup>Maurizio Cutolo, MD, MACR: Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCSS Ospedale Policlinico San Martino, Genova, Italy; <sup>9</sup>Eric L. Matteson: MD, MPH: Mayo Clinic College of Medicine and Science, Rochester, Minnesota; <sup>10</sup>Marco A. Cimmino, MD: Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy; <sup>11</sup>Daniele Saverino, MD, PhD: DIMES, University of Genova, Diagnostic Laboratory of Autoimmunology, IRCSS Ospedale Policlinico San Martino, Genova, Italy.</p></fn><fn id="acr270045-note-0002"><p>Drs Hysa and Camellino are co&#x02010;first authors and contributed equally to this work.</p></fn><fn id="acr270045-note-0003"><p>Additional supplementary information cited in this article can be found online in the Supporting Information section (<ext-link xlink:href="https://doi.org/10.1002/acr2.70045" ext-link-type="uri">https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.70045</ext-link>).</p></fn><fn id="acr270045-note-0004"><p>Author disclosures are available at <ext-link xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/acr2.70045" ext-link-type="uri">https://onlinelibrary.wiley.com/doi/10.1002/acr2.70045</ext-link>.</p></fn></fn-group></notes></front><body id="acr270045-body-0001"><sec id="acr270045-sec-0005"><title>INTRODUCTION</title><p>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely associated inflammatory diseases of older adults.<xref rid="acr270045-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> PMR is characterized by pain and stiffness in the neck, shoulder, and pelvic girdles, often accompanied by systemic inflammatory symptoms, such as fever and weight loss, and increased acute phase reactants.<xref rid="acr270045-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> GCA is the most common large vessel vasculitis (LVV) in patients aged &#x02265;50 years and is characterized by a granulomatous inflammation of the aorta and its branches.<xref rid="acr270045-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> PMR features are seen in up to 40% to 60% of newly diagnosed GCA, and approximately 16% to 21% of patients with PMR develop GCA at follow&#x02010;up.<xref rid="acr270045-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="acr270045-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="acr270045-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Accordingly, the concept of GCA&#x02010;PMR spectrum disease (GPSD) has been consolidated by experts in literature.<xref rid="acr270045-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="acr270045-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="acr270045-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>The pathogenetic mechanisms underlying these two conditions remain partially elusive. In GCA, histologic evidence points to infiltrates of effector T helper (Th) 1/17 cells and macrophages actively secreting interleukin (IL) 6, IL&#x02010;17, and interferon (IFN) &#x003b3;.<xref rid="acr270045-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Conversely, the main cellular elements involved in PMR appear to be macrophages, with histologic findings showing scarce infiltrates of T lymphocytes and B cells.<xref rid="acr270045-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="acr270045-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Recent data suggest an altered immune cell inhibitory signaling in GCA pathophysiology with a critical role of the cytotoxic T lymphocyte&#x02010;associated protein 4 (CTLA&#x02010;4) pathway.<xref rid="acr270045-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> This is not demonstrated in patients with isolated PMR.</p><p>Physiologically, immune checkpoint molecules (ICMs) are receptors that inhibit immune cell activation. They comprise the CTLA&#x02010;4 and the programmed cell death protein 1 (PD&#x02010;1).<xref rid="acr270045-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> CTLA&#x02010;4 blocks T cell activation by competing with CD28 for binding with CD80/86, resulting in the inhibition of T cell activation.<xref rid="acr270045-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> A soluble form of CTLA&#x02010;4 (sCTLA&#x02010;4) can also bind to its ligands and exert immunomodulatory effects via competitive binding.<xref rid="acr270045-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Similarly, PD&#x02010;1 is crucial for ending immune responses by binding its ligands, PD&#x02010;L1 and PD&#x02010;L2, which are mainly expressed on antigen&#x02010;presenting and other immune cells.<xref rid="acr270045-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Soluble forms of PD&#x02010;1 (sPD&#x02010;1) and PD&#x02010;L1 (sPD&#x02010;L1) have also been described, with sPD&#x02010;1 displaying a potential immunostimulatory effect by blocking the connection with PD&#x02010;L1, thus impeding the inhibitory message transduction.<xref rid="acr270045-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>Increased serum sCTLA&#x02010;4 concentrations have been reported in several autoimmune diseases,<xref rid="acr270045-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="acr270045-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and a reduced PD&#x02010;1/PD&#x02010;L1 signaling has been detected in the synovial microenvironment of patients with rheumatoid arthritis (RA), leading to the recent development of drugs stimulating this endogenous immune&#x02010;inhibitory pathway.<xref rid="acr270045-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="acr270045-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>The rationale for studying the role of soluble ICMs (sICMs) in PMR and GCA is provided by the accumulating evidence of drug&#x02010;induced PMR and/or GCA in patients with cancer treated with immune checkpoint inhibitors (ICIs).<xref rid="acr270045-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="acr270045-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="acr270045-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p></sec><sec id="acr270045-sec-0006"><title>PATIENTS AND METHODS</title><p>Consecutive patients diagnosed with PMR according to the criteria of Bird et al<xref rid="acr270045-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> were prospectively enrolled. Patients with PMR and overlapping GCA had to also satisfy the 1990 American College of Rheumatology criteria for GCA.<xref rid="acr270045-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Patients treated with glucocorticoids (GCs) for &#x0003e;15 days were excluded. A group of age&#x02010; and sex&#x02010;matched healthy controls was also included. Patients and controls signed an informed consent (CONSAZHQA_0001). This study was performed with the authorization of the Ethical Committee of San Martino Polyclinic Hospital, Genoa, Italy (EC 2013/4301).</p><sec id="acr270045-sec-0008"><title>Clinical and laboratory assessment</title><p>All patients underwent a complete clinical history and subsequent standardized physical examination. Disease duration, morning stiffness, presence of fever, weight loss, headache, jaw claudication, visual disturbance, spontaneous pain in the girdles and in the spine, limb claudication, and previous GC therapy were recorded.</p><p>White blood cells, platelets, hemoglobin, C&#x02010;reactive protein (CRP), and erythrocyte sedimentation rate (ESR) values were retrieved from patients&#x02019; routine laboratory evaluations performed in the week preceding the <sup>18</sup>F&#x02010;fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F&#x02010;FDG PET/CT) scan. Blood samples were collected the same day as the PET scan, before the infusion of FDG. Serum concentrations of sCTLA&#x02010;4, sPD&#x02010;1, sPD&#x02010;L1, and sPD&#x02010;L2 were measured by enzyme&#x02010;linked immunosorbent assay (EMELCA Bioscience, Clinge, the Netherlands) according to the manufacturer's instructions (see Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">1</xref> for further details). Each sample was diluted 1:10 and tested in duplicate. Serum IL&#x02010;6 was measured by enzyme&#x02010;linked immunosorbent assay (ImmunoTools GmbH, Friesoythe, Germany) according to the manufacturer's instructions. Each sample for IL&#x02010;6 concentrations was diluted 1:10 and tested in duplicate (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">1</xref>).</p></sec><sec id="acr270045-sec-0009"><title>
<styled-content style="fixed-case" toggle="no">PET</styled-content>/<styled-content style="fixed-case" toggle="no">CT</styled-content> acquisition</title><p>All patients underwent FDG PET/CT scanning. After a minimum of 6 hours of fasting, a dose of 4.8 to 5.2 MBq of <sup>18</sup>F&#x02010;FDG per kilogram body weight was injected through a peripheral vein catheter. Patients were placed in a quiet room and instructed to remain still. Data acquisition started &#x02265;60 minutes after intravenous administration of <sup>18</sup>F&#x02010;FDG. Patients underwent simultaneous FDG PET and CT imaging from the skull base to the thighs using an integrated PET/CT scanner (Hirez; Siemens Medical Solutions, Knoxville, TN, USA). In some patients, the scan also included legs and feet if they appeared to be involved clinically. PET scan raw data were reconstructed by means of ordered subset expectation maximization, and attenuation correction was performed using the CT scan raw data. The entire CT dataset was fused with the 3&#x02010;dimensional PET scan images using an integrated software interface (Syngo Image Fusion; Siemens, Erlangen, Germany) to create anatomic images superimposed with the FDG uptake.</p></sec><sec id="acr270045-sec-0010"><title>Image analysis</title><p>Joint and vascular uptake were scored both semiquantitatively with a visual score and quantitatively by an experienced nuclear medicine physician (M Bauckneht). All scans were reviewed by a second nuclear medicine physician (SM) to confirm protocol adherence and quality control. Regions of interest (ROIs) were placed on the anatomic CT scan images to identify four aortic segments (ascending, arch, descending, and abdominal), subclavian arteries, common carotid arteries, and iliac and femoral arteries. ROIs were drawn on the theoretical vessel wall to exclude the uptake of the blood inside the vessel lumen. A further region was drawn within the left ventricular chamber using the PET scan image to estimate the tracer concentration in the arterial blood (blood pool [BP]). To assess joint metabolism, CT&#x02010;based ROIs were bilaterally drawn on the glenohumeral, sternoclavicular, and coxofemoral joints and on the trochanteric and ischiatic bursae.</p><p>Arterial FDG uptake was quantified by calculating the mean standardized uptake value (SUV) within each ROI. To account for the contribution of FDG activity in the blood, results were expressed as the ratio between the mean SUV value of each ROI and BP ROI (SUV/BP), expressing true arterial wall metabolic activity; joint FDG uptake was considered without the BP ratio.</p><p>Arterial and joint uptake was visually graded using a four&#x02010;point scale as proposed by Walter et al<xref rid="acr270045-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>: 0 = no uptake present, 1 = uptake present but lower than liver uptake, 2 = similar to liver uptake, and 3 = uptake higher than liver uptake. To determine the prevalence of each finding, these scores were further subdivided as &#x0201c;negative&#x0201d; (0 and 1) and &#x0201c;positive&#x0201d; (2 and 3). In accordance with recently published consensus recommendations for PET scan interpretation in the context of LVV and PMR imaging, patients demonstrating grade 2 findings were deemed as possibly indicative of LVV, whereas those with grade 3 positive results were characterized as exhibiting active LVV, with this conclusion supported by evidence level II, grade B.<xref rid="acr270045-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> For each patient, the sum of the four&#x02010;point score of vascular and joint uptake was recorded as total vascular score, with a maximum score of 36, and total joint score (TJS), also considering the uptake in cervical and lumbar interspinous bursae, with a maximum score of 36.</p></sec><sec id="acr270045-sec-0011"><title>Statistical analysis</title><p>Analysis was performed using IBM SPSS Statistics software. The comparison of means was evaluated with Student's <italic toggle="yes">t</italic>&#x02010;test and analysis of variance with Bonferroni correction. Medians were compared with the Mann&#x02010;Whitney or Kruskall&#x02010;Wallis tests. The correlations between variables were evaluated with the Pearson test if normally distributed and with the Spearman rho test if nonparametric.</p><p>To account for the matched case&#x02010;control design, conditional logistic regression was applied to assess the association between sICMs and PMR/GCA, using two different cutoff strategies: the median and 75th percentile of control values. In case of complete separation between cases and controls, alternative metrics, including standardized effect size (Cohen d) and mean differences, were used to quantify the magnitude of association. Receiver operating characteristic (ROC) curve analysis was performed to determine the discriminative ability of sICMs in differentiating patients with PMR/GCA from healthy controls. Optimal cutoffs were identified using the Youden index, along with their corresponding sensitivity and specificity values. Statistical significance was assumed as <italic toggle="yes">P</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="acr270045-sec-0012"><title>RESULTS</title><sec id="acr270045-sec-0014"><title>Patient characteristics</title><p>Forty patients were included: 30 presented with clinically isolated PMR and 10 with GCA and associated PMR. Six (15%) patients were taking GCs, with a median dosage of 18.75 mg/day (range 7.5&#x02013;25) and a median duration of treatment of 10 days (range 3&#x02013;15). Ten patients (25%) exhibited grade 3 LVV at PET/CT. Of these, 4 presented as cranial GCA with overlapping PMR symptoms, whereas the remaining 6 had PMR with LV&#x02010;GCA. Other patient characteristics are outlined in Table&#x000a0;<xref rid="acr270045-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="acr270045-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Demographic and clinical characteristics of patients<xref rid="acr270045-note-0005" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Data</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Total number</td><td align="center" valign="top" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median age (range), years</td><td align="center" valign="top" rowspan="1" colspan="1">76 (50&#x02013;85)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with isolated PMR, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (75)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with PMR + GCA, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Already taking a GC, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systemic manifestations, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (42.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peripheral arthritis, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median disease duration (range), days</td><td align="center" valign="top" rowspan="1" colspan="1">87.5 (4&#x02013;1,086)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median MS (range), minutes</td><td align="center" valign="top" rowspan="1" colspan="1">60 (0&#x02013;360)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD WBC, 10<sup>9</sup>/L</td><td align="center" valign="top" rowspan="1" colspan="1">8.4 &#x000b1; 1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD PLT, 10<sup>9</sup>/L</td><td align="center" valign="top" rowspan="1" colspan="1">318.8 &#x000b1; 92.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD Hb, g/L</td><td align="center" valign="top" rowspan="1" colspan="1">124 &#x000b1; 14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean &#x000b1; SD ESR, mm/h</td><td align="center" valign="top" rowspan="1" colspan="1">67.7 &#x000b1; 33.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median CRP, mg/L</td><td align="center" valign="top" rowspan="1" colspan="1">31.6 (range 2&#x02013;124.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TJS, mean &#x000b1; SD</td><td align="center" valign="top" rowspan="1" colspan="1">18 &#x000b1; 6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TVS, mean &#x000b1; SD</td><td align="center" valign="top" rowspan="1" colspan="1">15 &#x000b1; 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Presence of grade&#x02010;3 LVV, n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (25)</td></tr></tbody></table><table-wrap-foot id="acr270045-ntgp-0002"><fn id="acr270045-note-0005"><label>*</label><p>CRP, C&#x02010;reactive protein; ESR, erythrocyte sedimentation rate; GC, glucocorticoid; GCA, giant cell arteritis; Hb, hemoglobin; LVV, large vessel vasculitis; MS, morning stiffness; PLT, platelet; PMR, polymyalgia rheumatica; TJS, total joint score; TVS, total vascular score; WBC: white blood cell.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acr270045-sec-0015"><title>Comparison between patients and controls</title><p>The mean &#x000b1; SD serum levels of sCTLA&#x02010;4, sPD&#x02010;1, sPD&#x02010;L1, and sPD&#x02010;L2 were significantly higher in patients than in healthy controls (<italic toggle="yes">P</italic> &#x0003c; 0.001 for all comparisons; Figure&#x000a0;<xref rid="acr270045-fig-0001" ref-type="fig">1</xref>). The mean &#x000b1; SD IL&#x02010;6 concentration was also significantly higher in patients than in controls (114.3 &#x000b1; 140.7 vs 3.1 &#x000b1; 1.88 pg/mL, <italic toggle="yes">P</italic> &#x0003c; 0.01).</p><fig position="float" fig-type="Figure" id="acr270045-fig-0001"><label>Figure 1</label><caption><p>Comparison between the mean and SDs between serum concentrations of the soluble immune checkpoint molecules in patients (gray) versus controls (black). CTLA&#x02010;4, cytotoxic T lymphocyte&#x02010;associated protein 4; PD&#x02010;1, programmed cell death protein 1; PD&#x02010;L, programmed cell death protein ligand.</p></caption><graphic xlink:href="ACR2-7-e70045-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="acr270045-sec-0016"><title>Correlations and subgroup analyses</title><p>Male patients had a higher mean concentration of sCTLA&#x02010;4 than female patients (12.7 vs 0.1 ng/mL, <italic toggle="yes">P</italic> = 0.03), whereas concentrations of PD&#x02010;1, PD&#x02010;L1, and PD&#x02010;L2 were comparable. Serum CTLA&#x02010;4 concentrations directly correlated with disease duration (r = 0.34, <italic toggle="yes">P</italic> = 0.03), whereas plasmatic PD&#x02010;L1 levels were inversely associated with the duration of morning stiffness (r = &#x02212;0.34, <italic toggle="yes">P</italic> = 0.04). No other correlations were observed between the remaining sICMs with the clinical, laboratory, and imaging characteristics (Table&#x000a0;<xref rid="acr270045-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="acr270045-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Correlations between soluble immune checkpoint molecules and IL&#x02010;6 with clinical, laboratory, and imaging features<xref rid="acr270045-note-0006" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" rowspan="2" valign="bottom" colspan="1">Table of correlations</th><th align="center" colspan="2" valign="bottom" rowspan="1">CTLA&#x02010;4</th><th align="center" colspan="2" valign="bottom" rowspan="1">PD&#x02010;1</th><th align="center" colspan="2" valign="bottom" rowspan="1">PD&#x02010;L1</th><th align="center" colspan="2" valign="bottom" rowspan="1">PD&#x02010;L2</th><th align="center" colspan="2" valign="bottom" rowspan="1">IL&#x02010;6</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Rho</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rho</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rho</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rho</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rho</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.06</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.71</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.51</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.27</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TVS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.62</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.38</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.54</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.59</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TJS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.68</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.28</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease duration</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.34</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.95</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.87</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.58</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.27</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.34</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.41</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.25</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.58</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.78</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.61</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESR</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.49</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.53</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.56</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.43</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLT</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.85</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.32</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.76</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.49</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hb</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.37</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.91</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.62</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.32</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.48</td></tr></tbody></table><table-wrap-foot id="acr270045-ntgp-0003"><fn id="acr270045-note-0006"><label>*</label><p>Significant <italic toggle="yes">p</italic>&#x02010;values with the related rho coefficients are reported in bold. CRP, C&#x02010;reactive protein; CTLA&#x02010;4, cytotoxic T lymphocyte&#x02010;associated protein 4; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; IL&#x02010;6, interleukin 6; MS, morning stiffness; PD&#x02010;1, programmed cell death protein 1; PD&#x02010;L, programmed cell death protein ligand; PLT, platelet; TJS, total joint score; TVS, total vascular score; WBC, white blood cell.</p></fn></table-wrap-foot></table-wrap><p>Concentrations of IL&#x02010;6 did not correlate with those of sICMs, nor with the clinical and imaging parameters. The differences in the concentration of sICMs between patients affected by both PMR and GCA compared with isolated PMR were not statistically significant, with <italic toggle="yes">P</italic> values ranging between 0.12 and 0.65 depending on the analyzed sICM (see Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">2</xref>). This was also the case when patients were stratified according to the presence of systemic manifestations (ie, fever and/or loss of weight), ischemic symptoms (ie, headache, visual disturbances, and jaw claudication), and peripheral arthritis and/or tenosynovitis (Supplementary Tables&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">3&#x02013;7</xref>). The six patients already taking GC treatment had sICM values comparable to those of the 34 GC&#x02010;naive patients. (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">8</xref>, see the paragraph below &#x0201c;Data related to GC&#x02010;naive patients&#x0201d;). Patients with grade 3 LVV did not significantly differ from the others in terms of mean concentrations of sICMs and IL&#x02010;6 (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">9</xref>).</p></sec><sec id="acr270045-sec-0017"><title>Results of the conditional logistic regression analysis</title><p>At conditional logistic regression analysis, all molecules showed significant discriminative capacity between patients and controls (<italic toggle="yes">P</italic> &#x0003c; 0.05). PD&#x02010;L1 demonstrated the strongest discriminative ability using the 75th percentile cutoff (odds ratio [OR] 134.33, <italic toggle="yes">P</italic> &#x0003c; 0.0001), followed by PD&#x02010;L2 (OR 63.00, <italic toggle="yes">P</italic> &#x0003c; 0.0001). For PD&#x02010;1, complete separation occurred between cases and controls (no overlapping values between groups), indicating excellent discriminative power that precluded OR calculation. CTLA&#x02010;4 showed moderate discriminative ability (OR 8.56, <italic toggle="yes">P</italic> = 0.0001), whereas IL&#x02010;6 showed significant but comparatively lower discrimination (OR 10.33 at the 75th percentile, <italic toggle="yes">P</italic> = 0.0105). These results suggest that elevated concentrations of sICMs, particularly PD&#x02010;1, PD&#x02010;L1, and PD&#x02010;L2, strongly distinguish patients with PMR/GCA from controls. For PD&#x02010;1, we used standardized effect size to quantify the magnitude of difference between groups. The standardized effect size was 0.78 (with 0.2, 0.5, and 0.8 conventionally representing small, medium, and large effects, respectively), confirming a substantial difference between cases and controls (Tables&#x000a0;<xref rid="acr270045-tbl-0003" ref-type="table">3</xref> and <xref rid="acr270045-tbl-0004" ref-type="table">4</xref>).</p><table-wrap position="float" id="acr270045-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Conditional logistic regression analysis of soluble immune checkpoint molecules in patients with polymyalgia rheumatica and giant cell arteritis compared with age&#x02010; and sex&#x02010;matched controls<xref rid="acr270045-note-0007" ref-type="table-fn">*</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Molecule</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median cutoff</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (median)</th><th align="center" valign="bottom" rowspan="1" colspan="1">75th cutoff</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (75th)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> values</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">CTLA&#x02010;4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">8.56</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">8.56</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD&#x02010;1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD&#x02010;L1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">39.00</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.90</td><td align="center" valign="top" rowspan="1" colspan="1">134.33</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD&#x02010;L2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">63.00</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">63.00</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL&#x02010;6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.40</td><td align="center" valign="top" rowspan="1" colspan="1">3.44</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.73</td><td align="center" valign="top" rowspan="1" colspan="1">10.33</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot id="acr270045-ntgp-0004"><fn id="acr270045-note-0007"><label>*</label><p>CTLA&#x02010;4, cytotoxic T lymphocyte&#x02010;associated protein 4; IL&#x02010;6, interleukin 6; NA, not applicable; OR (median), odds ratio using the control group median as the cutoff; OR (75th): odds ratio using the control group 75th percentile as the cutoff; PD&#x02010;1, programmed cell death protein 1; PD&#x02010;L, programmed cell death protein ligand.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="acr270045-tbl-0004" content-type="Table"><label>Table 4</label><caption><p>Programmed cell death protein 1 alternative analysis</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Metric</th><th align="center" valign="bottom" rowspan="1" colspan="1">Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Interpretation</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean difference</td><td align="center" valign="top" rowspan="1" colspan="1">2.52</td><td align="left" valign="top" rowspan="1" colspan="1">Average elevation in cases vs controls</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Effect size</td><td align="center" valign="top" rowspan="1" colspan="1">0.78</td><td align="left" valign="top" rowspan="1" colspan="1">Large standardized difference</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Distribution</td><td align="center" valign="top" rowspan="1" colspan="1">Nonoverlapping</td><td align="left" valign="top" rowspan="1" colspan="1">Complete separation between groups</td></tr></tbody></table></table-wrap></sec><sec id="acr270045-sec-0018"><title>
<styled-content style="fixed-case" toggle="no">ROC</styled-content> curve analysis, diagnostic performance, and sensitivity analyses</title><p>At ROC curves, PD&#x02010;1 showed the highest diagnostic accuracy (area under the curve [AUC] 1.000, optimal cutoff 0.96 ng/mL, sensitivity 100%, and specificity 97.5%) followed by PD&#x02010;L1 (AUC 0.971, optimal cutoff 1.98 ng/mL, sensitivity 97.5%, and specificity 92.5%) and PD&#x02010;L2 (AUC 0.919, optimal cutoff 0.51 ng/mL, sensitivity 90.0%, and specificity 92.5%). CTLA&#x02010;4 and IL&#x02010;6 showed good discrimination with AUCs of 0.744 and 0.814, respectively (Figure&#x000a0;<xref rid="acr270045-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="Figure" id="acr270045-fig-0002"><label>Figure 2</label><caption><p>ROC curves of soluble immune checkpoint molecules in polymyalgia rheumatica/giant cell arteritis: discriminative capacity between patients with polymyalgia rheumatica/giant cell arteritis and healthy controls. AUC, area under the curve; CTLA&#x02010;4, cytotoxic T lymphocyte&#x02010;associated protein 4; IL&#x02010;6, interleukin 6; PD&#x02010;1, programmed cell death protein 1; PD&#x02010;L, programmed cell death protein ligand; ROC, receiver operating characteristic.</p></caption><graphic xlink:href="ACR2-7-e70045-g005" position="anchor" id="jats-graphic-7"/></fig><p>Sensitivity analyses were performed to assess potential confounding. Stratification by sex showed consistent discriminatory performance of sICMs in both men (PD&#x02010;1 AUC 1.000, PD&#x02010;L1 AUC 1.000, and PD&#x02010;L2 AUC 0.930) and women (PD&#x02010;1 AUC 1.000, PD&#x02010;L1 AUC 0.963, and PD&#x02010;L2 AUC 0.919). Age&#x02010;stratified analysis (&#x0003c;70 vs &#x02265;70 years) revealed comparable AUCs for PD&#x02010;1 (1.000 vs 0.999), PD&#x02010;L1 (0.983 vs 0.965), and PD&#x02010;L2 (1.000 vs 0.889). CTLA&#x02010;4 and IL&#x02010;6 maintained moderate&#x02010;to&#x02010;good discrimination across all subgroups (AUC range 0.700&#x02013;0.930 and 0.702&#x02013;0.854, respectively). These results suggest that the association between sICMs and PMR/GCA is robust across age and sex subgroups (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">10</xref>).</p></sec><sec id="acr270045-sec-0019"><title>Data related to <styled-content style="fixed-case" toggle="no">GC</styled-content>&#x02010;naive patients</title><sec id="acr270045-sec-0020"><title>Comparison with healthy controls in <styled-content style="fixed-case" toggle="no">GC</styled-content>&#x02010;naive patients</title><p>The serum concentrations of the sICMs were significantly higher also in the subgroups of GC&#x02010;naive patients (n = 34) compared with healthy controls (Supplementary Figure&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">1</xref>; all <italic toggle="yes">P</italic> values &#x0003c;0.001). IL&#x02010;6 serum levels were also significantly higher in this subgroup compared with those of healthy controls (77 pg/mL vs 3.2 pg/mL, <italic toggle="yes">P</italic> &#x0003c; 0.001).</p></sec><sec id="acr270045-sec-0021"><title>Correlations and subgroup analyses</title><p>A weak&#x02010;to&#x02010;moderate positive correlation emerged between serum PD&#x02010;L1 and TJS (r = 0.38, <italic toggle="yes">P</italic> = 0.03; Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">11</xref>). No significant differences were found in the median sICM concentrations between PMR/GCA versus isolated PMR (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">12</xref>) or when stratifying by vascular/musculoskeletal manifestations (Supplementary Tables&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">13&#x02013;17</xref>), although CTLA&#x02010;4 showed a trend toward higher values in patients with hand tenosynovitis (median 11.8 [range 4.2&#x02013;15.5] vs median 0.1 [range 0.1&#x02013;10.2], <italic toggle="yes">P</italic> = 0.07).</p></sec><sec id="acr270045-sec-0022"><title>Conditional logistic regression analysis and <styled-content style="fixed-case" toggle="no">ROC</styled-content> analyses in <styled-content style="fixed-case" toggle="no">GC</styled-content>&#x02010;naive patients</title><p>Conditional logistic regression confirmed the strong discriminative capacity of sICMs between patients and controls, particularly for PD&#x02010;L1 (OR 132.47, <italic toggle="yes">P</italic> &#x0003c; 0.0001) and PD&#x02010;L2 (OR 60.00, <italic toggle="yes">P</italic> &#x0003c; 0.0001). PD&#x02010;1 showed complete separation between groups (effect size 0.80). ROC analysis demonstrated excellent discrimination for PD&#x02010;1 (AUC 1.000), PD&#x02010;L1 (AUC 0.969), and PD&#x02010;L2 (AUC 0.927), whereas CTLA&#x02010;4 and IL&#x02010;6 showed good&#x02010;to&#x02010;moderate performance (AUCs of 0.730 and 0.813, respectively). The results were consistent with those of the total cohort analysis (Supplementary Table&#x000a0;<xref rid="acr270045-supitem-0002" ref-type="supplementary-material">18</xref>).</p></sec></sec></sec><sec sec-type="discussion" id="acr270045-sec-0023"><title>DISCUSSION</title><p>ICIs are increasingly used for treating several types of cancer.<xref rid="acr270045-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Despite being successful weapons in the treatment of malignancies, they are associated with a multitude of immune&#x02010;mediated adverse effects, including endocrine, gastroenterologic, renal, cutaneous, and articular manifestations.<xref rid="acr270045-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> New&#x02010;onset inflammatory arthritis occurs in approximately 5% to 7% of patients with cancer treated with ICIs.<xref rid="acr270045-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="acr270045-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Other possible manifestations include myositis, sicca syndrome, and sarcoidosis, as well as PMR and GCA.<xref rid="acr270045-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>The occurrence of PMR and GCA in patients treated with ICIs also hints at an imbalance of these regulatory pathways in the pathogenesis of their idiopathic forms. In fact, temporal artery specimens from patients with active GCA have shown low levels of PD&#x02010;L1 and high levels of PD&#x02010;1 transcripts, suggesting defective immunoregulatory mechanisms that lead to vascular inflammation in GCA.<xref rid="acr270045-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> In contrast, arteries from healthy donors showed high levels of PD&#x02010;L1 transcripts but almost a complete absence of PD&#x02010;1 transcripts, indicating a lack of T cells in the normal vessel wall.<xref rid="acr270045-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Additionally, the use of an anti&#x02013;PD&#x02010;1 antibody in a mouse model of GCA increased vascular inflammation and T cell infiltration.<xref rid="acr270045-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="acr270045-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>In a cross&#x02010;sectional study on patients with GCA, circulating PD&#x02010;1+ Th cells were reduced in comparison those of healthy controls.<xref rid="acr270045-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Circulating Th cells expressing the negative checkpoint V&#x02010;domain Ig&#x02010;containing suppressor of T cell activation (VISTA) were also reduced in number. On the other hand, arteritic lesions from diagnostic temporal artery biopsies were increased in VISTA&#x02010;expressing cells and in PD&#x02010;L1&#x02013;expressing cells.<xref rid="acr270045-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> These findings suggest a deficiency of the immune checkpoint activity in GCA, a hypothesis that is supported by cases of ICI&#x02010;induced vasculitides.<xref rid="acr270045-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Although the expression of the PD&#x02010;1/PD&#x02010;L1 immune checkpoint has not been reported yet in patients with isolated PMR, there are several cases of onset of PMR symptoms in patients treated with anti&#x02013;PD&#x02010;1/anti&#x02013;PD&#x02010;L1 agents, again suggesting a potential role of PD&#x02010;1/PD&#x02010;L1 signal in PMR pathogenesis<xref rid="acr270045-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> (Figure&#x000a0;<xref rid="acr270045-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="Figure" id="acr270045-fig-0003"><label>Figure 3</label><caption><p>Possible role of soluble immune checkpoint molecules in PMR and GCA. CTLA&#x02010;4, cytotoxic T lymphocyte&#x02010;associated protein 4; GCA, giant cell arteritis; ICI: immune checkpoints inhibitor; IL, interleukin; INF, interferon; MHC, major histocompatibility complex; PD&#x02010;1, programmed cell death protein 1; PD&#x02010;L, programmed cell death protein ligand; PMR, polymyalgia rheumatica; s, soluble; TCR, T cell receptor; Th, T helper.</p></caption><graphic xlink:href="ACR2-7-e70045-g004" position="anchor" id="jats-graphic-9"/></fig><p>In the current study, we analyzed the soluble forms of CTLA&#x02010;4 and PD&#x02010;1 and its ligands in patients with PMR and GCA and assessed whether different clinical, laboratory, and imaging characteristics could be attributed to the different expression and functions of immune checkpoint markers. Patients in this study had significantly higher levels of sCTLA&#x02010;4, sPD&#x02010;1, sPD&#x02010;L1, and sPD&#x02010;L2 than healthy controls. This finding is in line with the existing literature in several other autoimmune diseases.<xref rid="acr270045-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> However, we did not find significant correlations between concentrations of these markers and disease duration, morning stiffness, CRP, ESR, or the total burden of vascular and articular inflammation as assessed by FDG PET/CT scan. Indeed, the isolated significant associations between sCTLA&#x02010;4 and disease duration and between PD&#x02010;L1 and morning stiffness duration were weak and likely not relevant from a clinical and pathophysiologic point of view. Although certain differences, such as the trend toward lower CTLA&#x02010;4 serum concentrations in patients with PMR with concomitant GCA compared with isolated PMR, may be biologically plausible given the immunoregulatory role of CTLA&#x02010;4, their clinical relevance remains uncertain. One possible explanation is that in GCA, the heightened immune activation and altered regulatory T cells function may lead to increased CTLA&#x02010;4 use at the tissue level, reducing its circulating levels as a compensatory response. Supporting this, recent evidence suggests that while regulatory T cells in GCA are numerically reduced and functionally impaired they up&#x02010;regulate CTLA&#x02010;4 and are more susceptible to depletion, indicating a potential increase in local demand for CTLA&#x02010;4&#x02013;mediated immunoregulation.<xref rid="acr270045-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> However, without established minimal clinically important differences for sICMs in autoimmune diseases, the significance of these variations remains unclear and warrants further investigation.<xref rid="acr270045-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>In GC&#x02010;naive patients, a positive correlation emerged between PD&#x02010;L1 and the TJS. This finding is intriguing given that PD&#x02010;L1 expression has been found to be elevated in the synovial tissue of patients with inflammatory arthritis, where it may represent an attempted compensatory mechanism to control local inflammation.<xref rid="acr270045-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Similar mechanisms have been described in RA, where increased PD&#x02010;L1 expression in the synovium correlates with disease activity and joint involvement. However, the modest strength of this correlation in our cohort, combined with its absence in the total population, suggests that its clinical relevance requires validation in larger studies.</p><p>We also tested whether there are differences in circulating ICMs in patients with associated GCA. No differences were detected in comparison with patients with isolated PMR, either in terms of clinical presentation (eg, presence or absence of headache, jaw claudication, or systemic inflammation) or imaging&#x02010;detected vasculitis. Moreover, no significant differences were observed in the concentrations of sICM between GC&#x02010;treated patients and those naive to prednisone. However, it is important to note that this subgroup of GC&#x02010;treated patients may have been limited by the small sample size of GC&#x02010;treated patients (n = 6).</p><p>Preliminary data from a pharmacovigilance study suggested preferential involvement of the CTLA&#x02010;4 pathway in the development of ICI&#x02010;induced GCA, as patients with temporal arteritis were more likely to have received anti&#x02013;CTLA&#x02010;4 treatment.<xref rid="acr270045-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Furthermore, a recent multicenter clinical study of patients with ICI&#x02010;induced GCA revealed that individuals receiving dual therapy with CTLA&#x02010;4 and PD&#x02010;1/L1 blockers more frequently exhibited cranial involvement, including permanent visual loss, compared with those treated with PD&#x02010;1 blockers alone, highlighting the significant role of CTLA&#x02010;4 signaling.<xref rid="acr270045-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> In contrast, a study by Zhang et al pointed to a significant role for the PD&#x02010;1 pathway.<xref rid="acr270045-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> In this respect, a recent systematic review summarizing data from 44 patients with ICI&#x02010;induced GCA revealed that most individuals developing GCA after ICI treatment were receiving PD&#x02010;1/PD&#x02010;L1 blockers (57%).<xref rid="acr270045-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> A trial of abatacept, a CTLA&#x02010;4&#x02010;Ig used for the treatment of RA, in patients with GCA showed a slightly significant increase in relapse&#x02010;free survival at 12 months compared with controls.<xref rid="acr270045-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Although the overall results of this trial were positive, the small effect of abatacept may suggest that this pathway is not a pivotal target in GCA, and indeed, an industry&#x02010;sponsored trial on the use of subcutaneous abatacept in patients with GCA (NCT03192969) has been withdrawn. The results of a phase III trial on the use of abatacept monotherapy in patients with early&#x02010;onset PMR, without associated GC for the first 12 weeks of treatment, showed that the effect of abatacept alone is not strong enough to justify larger studies in early PMR (primary endpoint of low disease activity reached in 50% of patients receiving abatacept vs 22% of individuals of the placebo group, <italic toggle="yes">P</italic> = 0.07).<xref rid="acr270045-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p><p>An interesting question to consider is whether ICI&#x02010;induced rheumatic diseases serve as reliable models for studying their idiopathic disease counterparts. A report on six cases of ICI&#x02010;induced PMR showed imaging characteristics comparable with those of usual PMR.<xref rid="acr270045-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> In a mixed cohort of patients with ICI&#x02010;induced PMR and cases from a literature review, many showed atypical features: peripheral synovitis (including unusual sites such as the elbow), positivity of autoantibodies, and sicca syndrome.<xref rid="acr270045-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> In a cohort of 14 patients with ICI&#x02010;induced PMR, peripheral arthritis was present in 57%, compared with 28% of the control group composed of 43 patients with &#x0201c;classic&#x0201d; PMR.<xref rid="acr270045-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> In our study, 25% of patients presented with peripheral arthritis, but its presence was not correlated with the concentrations of sICM.</p><p>The study of ICI&#x02010;induced rheumatic disease is in its infancy. Several mechanisms have been postulated to explain the pathophysiology of immune&#x02010;related adverse events, including a pre&#x02010;existing and latent autoimmunity.<xref rid="acr270045-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Another point suggested by the ICIs is that PMR, considered by some authors an autoinflammatory disease rather than an autoimmune one,<xref rid="acr270045-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> may be triggered also by autoimmune mechanisms.<xref rid="acr270045-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> At the same time, it is plausible that primary PMR and ICI&#x02010;induced PMR could represent distinct conditions, with the former potentially primarily driven by innate immunity (macrophages) and the latter by the aberrant activation of T cells resulting from ICI treatment. In fact, a recent cross&#x02010;sectional, observational study from the Netherlands compared the clinical, laboratory, and imaging characteristics of patients with ICI&#x02010;induced PMR with those of primary PMR, suggesting that ICI&#x02010;induced PMR may have a milder course with less inflammation as assessed by <sup>18</sup>F&#x02010;FDG PET/CT.<xref rid="acr270045-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> Moreover, a recent systematic review identified differences in sex prevalence, with ICI&#x02010;induced PMR showing a higher occurrence in men, and lower incidence of remitting seronegative symmetric synovitis with pitting edema, greater prevalence of normal or slightly elevated markers of inflammation, and lower relapse rate compared with primary PMR.<xref rid="acr270045-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>The results of our study demonstrate that ICMs are involved in PMR and GCA, as highlighted by the increase of their soluble forms in this cohort. However, the CTLA&#x02010;4 and PD&#x02010;1 pathways do not appear to play a central role in GPSD. This is supported by the absence of correlation with articular and vascular manifestations in our patients and by the limited efficacy of abatacept in treating GCA and PMR, which contrasts with its success in other autoimmune rheumatic diseases characterized by predominant T cell activation, such as RA.<xref rid="acr270045-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="acr270045-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> The elevated serum concentrations of sCTLA&#x02010;4 observed in our cohort indicate that patients with PMR may inherently trigger an immune&#x02010;regulatory mechanism to curb T cell hyperactivity. However, this response alone might be insufficient, as indicated by the limited efficacy of abatacept (CTLA&#x02010;4&#x02010;Ig fusion protein) in PMR,<xref rid="acr270045-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> which suggests that the innate immune system could also play a predominant role in the disease process<xref rid="acr270045-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> (Figure&#x000a0;<xref rid="acr270045-fig-0003" ref-type="fig">3</xref>).</p><p>Although our study demonstrates significantly higher levels of sICMs in patients compared with controls, the interpretation of differences between patient subgroups (eg, PMR vs PMR + GCA or GC&#x02010;treated vs GC&#x02010;naive) requires caution. The absence of established minimal clinically important differences for sICMs in rheumatic diseases, combined with our sample size, makes it challenging to determine the clinical relevance of these subgroup variations. For instance, the trend toward lower CTLA&#x02010;4 levels in patients with PMR with concomitant GCA compared with those with PMR alone might reflect biologic differences in immune regulation, but larger studies are needed to establish clinically meaningful thresholds and confirm these findings.</p><p>The strengths of the study include the prospective inclusion of consecutive, unselected patients and the accurate clinical, laboratory, and imaging assessment of all the patients. To the best of our knowledge, this is the largest study analyzing serum ICMs in patients with PMR and GCA.</p><p>The limitations of this study include the fact that a few patients were already taking GC treatment at the time of the assessments. However, treatment duration was short, cumulative dosage was low, and these patients had mean concentrations of sICMs comparable with GC&#x02010;naive patients. Although we did not systematically collect data on comorbidities and concomitant medications, the consistency of sICM levels across different subgroup analyses (age, sex, and clinical manifestations) supports the robustness of our findings. Another limitation is represented by the analysis of the sICM only, without studying the membrane&#x02010;bound counterparts. However, we have previously demonstrated that the soluble form of CTLA&#x02010;4 may be a good &#x0201c;proxy&#x0201d; for the activity of the membrane&#x02010;bound form, as showed by flow cytometry analysis.<xref rid="acr270045-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
</p><p>sICMs are significantly elevated in patients with PMR and GCA and effectively differentiate them from healthy controls, particularly PD&#x02010;1, PD&#x02010;L1, and PD&#x02010;L2. However, these molecules do not appear to differentiate patients with or without LVV, and they cannot be used to distinguish disease phenotypes. The increased serum concentrations of co&#x02010;inhibitory molecules during active disease may reflect an immune&#x02010;modulatory feedback mechanism aimed at controlling T cell hyperactivity, suggesting a complex involvement of adaptive immunity in addition to the innate immune response. Despite their consistent elevation across different patient subgroups (age, sex, and GC treatment status), their potential utility as biomarkers requires further validation. Larger prospective studies, including patients receiving specific treatments, are needed to determine clinically meaningful thresholds and assess their prognostic significance. These future studies may also provide deeper pathophysiologic insights into the mechanisms underlying PMR and GCA.</p></sec><sec id="acr270045-sec-0025"><title>AUTHOR CONTRIBUTIONS</title><p>All authors contributed to at least one of the following manuscript preparation roles: conceptualization AND/OR methodology, software, investigation, formal analysis, data curation, visualization, and validation AND drafting or reviewing/editing the final draft. As corresponding author, Dr Camellino confirms that all authors have provided the final approval of the version to be published, and takes responsibility for the affirmations regarding article submission (eg, not under consideration by another journal), the integrity of the data presented, and the statements regarding compliance with institutional review board/Declaration of Helsinki requirements.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acr270045-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Disclosure form</bold>.</p></caption><media xlink:href="ACR2-7-e70045-s001.pdf"/></supplementary-material><supplementary-material id="acr270045-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Appendix S1:</bold> Supplementary Information</p></caption><media xlink:href="ACR2-7-e70045-s002.docx"/></supplementary-material></sec></body><back><ack id="acr270045-sec-0024"><title>ACKNOWLEDGMENT</title><p>Figure&#x000a0;<xref rid="acr270045-fig-0003" ref-type="fig">3</xref> was created with <ext-link xlink:href="http://www.biorender.com" ext-link-type="uri">www.biorender.com</ext-link> (agreement number ZK27AI1M1T from the Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy). Open access publishing facilitated by Universita degli Studi di Genova, as part of the Wiley &#x02010; CRUI&#x02010;CARE agreement.</p></ack><ref-list content-type="cited-references" id="acr270045-bibl-0001"><title>REFERENCES</title><ref id="acr270045-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acr270045-cit-0001">
<string-name>
<surname>Buttgereit</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matteson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Dejaco</surname>
<given-names>C</given-names>
</string-name>. <article-title>Polymyalgia rheumatica and giant cell arteritis</article-title>. <source>JAMA</source>
<year>2020</year>;<volume>324</volume>(<issue>10</issue>):<fpage>993</fpage>&#x02013;<lpage>994</lpage>.<pub-id pub-id-type="pmid">32897333</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acr270045-cit-0002">
<string-name>
<surname>Camellino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Giusti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Girasole</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Pathogenesis, diagnosis and management of polymyalgia rheumatica</article-title>. <source>Drugs Aging</source>
<year>2019</year>;<volume>36</volume>(<issue>11</issue>):<fpage>1015</fpage>&#x02013;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">31493201</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acr270045-cit-0003">
<string-name>
<surname>Bilton</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Mollan</surname>
<given-names>SP</given-names>
</string-name>. <article-title>Giant cell arteritis: reviewing the advancing diagnostics and management</article-title>. <source>Eye (Lond)</source>
<year>2023</year>;<volume>37</volume>(<issue>12</issue>):<fpage>2365</fpage>&#x02013;<lpage>2373</lpage>.<pub-id pub-id-type="pmid">36788362</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acr270045-cit-0004">
<string-name>
<surname>Dejaco</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Duftner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buttgereit</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease</article-title>. <source>Rheumatology (Oxford)</source>
<year>2017</year>;<volume>56</volume>(<issue>4</issue>):<fpage>506</fpage>&#x02013;<lpage>515</lpage>.<pub-id pub-id-type="pmid">27481272</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acr270045-cit-0005">
<string-name>
<surname>Camellino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Matteson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Buttgereit</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Monitoring and long&#x02010;term management of giant cell arteritis and polymyalgia rheumatica</article-title>. <source>Nat Rev Rheumatol</source>
<year>2020</year>;<volume>16</volume>(<issue>9</issue>):<fpage>481</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">32759996</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acr270045-cit-0006">
<string-name>
<surname>De Miguel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Macchioni</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Conticini</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica</article-title>. <source>Rheumatology (Oxford)</source>
<year>2024</year>;<volume>63</volume>(<issue>1</issue>):<fpage>158</fpage>&#x02013;<lpage>164</lpage>.<pub-id pub-id-type="pmid">37129541</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acr270045-cit-0007">
<string-name>
<surname>Tomelleri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>van der Geest</surname>
<given-names>KSM</given-names>
</string-name>, <string-name>
<surname>Khurshid</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Disease stratification in GCA and PMR: state of the art and future perspectives</article-title>. <source>Nat Rev Rheumatol</source>
<year>2023</year>;<volume>19</volume>(<issue>7</issue>):<fpage>446</fpage>&#x02013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">37308659</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acr270045-cit-0008">
<string-name>
<surname>Dejaco</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kerschbaumer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Aletaha</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Treat&#x02010;to&#x02010;target recommendations in giant cell arteritis and polymyalgia rheumatica</article-title>. <source>Ann Rheum Dis</source>
<year>2024</year>;<volume>83</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">36828585</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acr270045-cit-0009">
<string-name>
<surname>Hysa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ehlers</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review</article-title>. <source>Rheumatology (Oxford)</source>
<year>2024</year>;<volume>63</volume>(<issue>2</issue>):<fpage>285</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">37672017</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acr270045-cit-0010">
<string-name>
<surname>Akiyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ohtsuki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>GJ</given-names>
</string-name>, et al. <article-title>Innate and adaptive immunity in giant cell arteritis</article-title>. <source>Front Immunol</source>
<year>2021</year>;<volume>11</volume>:<elocation-id>621098</elocation-id>.<pub-id pub-id-type="pmid">33717054</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acr270045-cit-0011">
<string-name>
<surname>Meliconi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pulsatelli</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Uguccioni</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment</article-title>. <source>Arthritis Rheum</source>
<year>1996</year>;<volume>39</volume>(<issue>7</issue>):<fpage>1199</fpage>&#x02013;<lpage>1207</lpage>.<pub-id pub-id-type="pmid">8670331</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acr270045-cit-0012">
<string-name>
<surname>Hysa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gotelli</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sammor&#x000ec;</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review</article-title>. <source>Autoimmun Rev</source>
<year>2022</year>;<volume>21</volume>(<issue>2</issue>):<elocation-id>102995</elocation-id>.<pub-id pub-id-type="pmid">34798314</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acr270045-cit-0013">
<string-name>
<surname>R&#x000e9;gnier</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Le Joncour</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maciejewski&#x02010;Duval</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>CTLA&#x02010;4 pathway is instrumental in giant cell arteritis</article-title>. <source>Circ Res</source>
<year>2023</year>;<volume>133</volume>(<issue>4</issue>):<fpage>298</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">37435729</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acr270045-cit-0014">
<string-name>
<surname>He</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>C</given-names>
</string-name>. <article-title>Immune checkpoint signaling and cancer immunotherapy</article-title>. <source>Cell Res</source>
<year>2020</year>;<volume>30</volume>(<issue>8</issue>):<fpage>660</fpage>&#x02013;<lpage>669</lpage>.<pub-id pub-id-type="pmid">32467592</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acr270045-cit-0015">
<string-name>
<surname>Simone</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pesce</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Antola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>The soluble form of CTLA&#x02010;4 from serum of patients with autoimmune diseases regulates T&#x02010;cell responses</article-title>. <source>BioMed Res Int</source>
<year>2014</year>;<volume>2014</volume>:<elocation-id>215763</elocation-id>.<pub-id pub-id-type="pmid">24605322</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="acr270045-cit-0016">
<string-name>
<surname>Sharpe</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Pauken</surname>
<given-names>KE</given-names>
</string-name>. <article-title>The diverse functions of the PD1 inhibitory pathway</article-title>. <source>Nat Rev Immunol</source>
<year>2018</year>;<volume>18</volume>(<issue>3</issue>):<fpage>153</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">28990585</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="acr270045-cit-0017">
<string-name>
<surname>Zhu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>J</given-names>
</string-name>. <article-title>Soluble PD&#x02010;1 and PD&#x02010;L1: predictive and prognostic significance in cancer</article-title>. <source>Oncotarget</source>
<year>2017</year>;<volume>8</volume>(<issue>57</issue>):<fpage>97671</fpage>&#x02013;<lpage>97682</lpage>.<pub-id pub-id-type="pmid">29228642</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="acr270045-cit-0018">
<string-name>
<surname>Yuan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Soluble form of immune checkpoints in autoimmune diseases</article-title>. <source>J Autoimmun</source>
<year>2024</year>;<volume>147</volume>:<elocation-id>103278</elocation-id>.<pub-id pub-id-type="pmid">38943864</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="acr270045-cit-0019">
<string-name>
<surname>Raptopoulou</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Bertsias</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Makrygiannakis</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>The programmed death 1/programmed death ligand 1 inhibitory pathway is up&#x02010;regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis</article-title>. <source>Arthritis Rheum</source>
<year>2010</year>;<volume>62</volume>(<issue>7</issue>):<fpage>1870</fpage>&#x02013;<lpage>1880</lpage>.<pub-id pub-id-type="pmid">20506224</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="acr270045-cit-0020">
<string-name>
<surname>Tuttle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Drescher</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sim&#x000f3;n&#x02010;Campos</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>A phase 2 trial of peresolimab for adults with rheumatoid arthritis</article-title>. <source>N Engl J Med</source>
<year>2023</year>;<volume>388</volume>(<issue>20</issue>):<fpage>1853</fpage>&#x02013;<lpage>1862</lpage>.<pub-id pub-id-type="pmid">37195941</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="acr270045-cit-0021">
<string-name>
<surname>Goldstein</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Gedmintas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Todd</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Drug&#x02010;associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA&#x02010;4</article-title>. <source>Arthritis Rheumatol</source>
<year>2014</year>;<volume>66</volume>(<issue>3</issue>):<fpage>768</fpage>&#x02013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">24574239</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="acr270045-cit-0022">
<string-name>
<surname>Calabrese</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cappelli</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Kostine</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Polymyalgia rheumatica&#x02010;like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature</article-title>. <source>RMD Open</source>
<year>2019</year>;<volume>5</volume>(<issue>1</issue>):<elocation-id>e000906</elocation-id>.<pub-id pub-id-type="pmid">31168414</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="acr270045-cit-0023">
<string-name>
<surname>Hysa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Casabella</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gotelli</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms</article-title>. <source>Autoimmun Rev</source>
<year>2024</year>;<volume>23</volume>(<issue>7&#x02013;8</issue>):<elocation-id>103589</elocation-id>.<pub-id pub-id-type="pmid">39117006</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="acr270045-cit-0024">
<string-name>
<surname>Bird</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Esselinckx</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Dixon</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>An evaluation of criteria for polymyalgia rheumatica</article-title>. <source>Ann Rheum Dis</source>
<year>1979</year>;<volume>38</volume>(<issue>5</issue>):<fpage>434</fpage>&#x02013;<lpage>439</lpage>.<pub-id pub-id-type="pmid">518143</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="acr270045-cit-0025">
<string-name>
<surname>Hunder</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Bloch</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>BA</given-names>
</string-name>, et al. <article-title>The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis</article-title>. <source>Arthritis Rheum</source>
<year>1990</year>;<volume>33</volume>(<issue>8</issue>):<fpage>1122</fpage>&#x02013;<lpage>1128</lpage>.<pub-id pub-id-type="pmid">2202311</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="acr270045-cit-0026">
<string-name>
<surname>Walter</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Melzer</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Schindler</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>The value of [<sup>18</sup>F]FDG&#x02010;PET in the diagnosis of large&#x02010;vessel vasculitis and the assessment of activity and extent of disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2005</year>;<volume>32</volume>(<issue>6</issue>):<fpage>674</fpage>&#x02013;<lpage>681</lpage>.<pub-id pub-id-type="pmid">15747154</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="acr270045-cit-0027">
<string-name>
<surname>Slart</surname>
<given-names>RHJA</given-names>
</string-name>; <collab collab-type="authors">Writing group; Reviewer group</collab>
; <collab collab-type="authors">Members of EANM Cardiovascular</collab>
; <collab collab-type="authors">Members of EANM Infection &#x00026; Inflammation</collab>
; <collab collab-type="authors">Members of Committees</collab>
, <collab collab-type="authors">SNMMI Cardiovascular</collab>
; <collab collab-type="authors">Members of Council</collab>
, <collab collab-type="authors">PET Interest Group</collab>
; <collab collab-type="authors">Members of ASNC</collab>
; <collab collab-type="authors">EANM Committee Coordinator</collab>
. <article-title>FDG&#x02010;PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<year>2018</year>;<volume>45</volume>(<issue>7</issue>):<fpage>1250</fpage>&#x02013;<lpage>1269</lpage>.<pub-id pub-id-type="pmid">29637252</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="acr270045-cit-0028">
<string-name>
<surname>Shiravand</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Khodadadi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kashani</surname>
<given-names>SMA</given-names>
</string-name>, et al. <article-title>Immune checkpoint inhibitors in cancer therapy</article-title>. <source>Curr Oncol</source>
<year>2022</year>;<volume>29</volume>(<issue>5</issue>):<fpage>3044</fpage>&#x02013;<lpage>3060</lpage>.<pub-id pub-id-type="pmid">35621637</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="acr270045-cit-0029">
<string-name>
<surname>Abdel&#x02010;Wahab</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Suarez&#x02010;Almazor</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy</article-title>. <source>Rheumatology (Oxford)</source>
<year>2019</year>;<volume>58</volume>(<issue>suppl 7</issue>):<fpage>vii40</fpage>&#x02013;<lpage>vii48</lpage>.<pub-id pub-id-type="pmid">31816084</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="acr270045-cit-0030">
<string-name>
<surname>Kostine</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rouxel</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Barnetche</surname>
<given-names>T</given-names>
</string-name>, et al; <collab collab-type="authors">FHU ACRONIM</collab>
. <article-title>Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer&#x02010;clinical aspects and relationship with tumour response: a single&#x02010;centre prospective cohort study</article-title>. <source>Ann Rheum Dis</source>
<year>2018</year>;<volume>77</volume>(<issue>3</issue>):<fpage>393</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">29146737</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="acr270045-cit-0031">
<string-name>
<surname>Ladouceur</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jamal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Saltman</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Chronicity of immune checkpoint inhibitor&#x02010;associated inflammatory arthritis after immunotherapy discontinuation: results from the Canadian Research Group of Rheumatology in Immuno&#x02010;Oncology Database</article-title>. <source>ACR Open Rheumatol</source>
<year>2025</year>;<volume>7</volume>(<issue>2</issue>):<elocation-id>e70002</elocation-id>.<pub-id pub-id-type="pmid">39964344</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="acr270045-cit-0032">
<string-name>
<surname>Reid</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cappelli</surname>
<given-names>LC</given-names>
</string-name>. <article-title>Treatment of rheumatic adverse events of cancer immunotherapy</article-title>. <source>Best Pract Res Clin Rheumatol</source>
<year>2022</year>;<volume>36</volume>(<issue>4</issue>):<elocation-id>101805</elocation-id>.<pub-id pub-id-type="pmid">36539321</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="acr270045-cit-0033">
<string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>GJ</given-names>
</string-name>, et al. <article-title>Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis</article-title>. <source>Proc Natl Acad Sci U S A.</source>
<year>2017</year>;<volume>114</volume>(<issue>6</issue>):<fpage>E970</fpage>&#x02013;<lpage>E979</lpage>.<pub-id pub-id-type="pmid">28115719</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="acr270045-cit-0034">
<string-name>
<surname>Watanabe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Immune checkpoint dysfunction in large and medium vessel vasculitis</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<year>2017</year>;<volume>312</volume>(<issue>5</issue>):<fpage>H1052</fpage>&#x02013;<lpage>H1059</lpage>.<pub-id pub-id-type="pmid">28314758</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="acr270045-cit-0035">
<string-name>
<surname>Hid Cadena</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Reitsema</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Huitema</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA</article-title>. <source>Front Immunol</source>
<year>2019</year>;<volume>10</volume>:<fpage>1638</fpage>.<pub-id pub-id-type="pmid">31379838</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="acr270045-cit-0036">
<string-name>
<surname>Boland</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Heath</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sandigursky</surname>
<given-names>S</given-names>
</string-name>. <article-title>Immune checkpoint inhibitors and vasculitis</article-title>. <source>Curr Opin Rheumatol</source>
<year>2020</year>;<volume>32</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">31599800</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="acr270045-cit-0037">
<string-name>
<surname>Manzo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Isetta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Natale</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Identification and classification of polymyalgia rheumatica (PMR) and PMR&#x02010;like syndromes following immune checkpoint inhibitors (ICIs) therapy: discussion points and grey areas emerging from a systematic review of published literature</article-title>. <source>Medicines (Basel)</source>
<year>2020</year>;<volume>7</volume>(<issue>11</issue>):<fpage>68</fpage>.<pub-id pub-id-type="pmid">33153016</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="acr270045-cit-0038">
<string-name>
<surname>Saverino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Simone</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bagnasco</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The soluble CTLA&#x02010;4 receptor and its role in autoimmune diseases: an update</article-title>. <source>Auto Immun Highlights</source>
<year>2010</year>;<volume>1</volume>(<issue>2</issue>):<fpage>73</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26000110</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="acr270045-cit-0039">
<string-name>
<surname>Canavan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Floudas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Veale</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>The PD&#x02010;1:PD&#x02010;L1 axis in inflammatory arthritis</article-title>. <source>BMC Rheumatol</source>
<year>2021</year>;<volume>5</volume>(<issue>1</issue>):<fpage>1</fpage>.<pub-id pub-id-type="pmid">33423684</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="acr270045-cit-0040">
<string-name>
<surname>Salem</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Manouchehri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moey</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study</article-title>. <source>Lancet Oncol</source>
<year>2018</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1579</fpage>&#x02013;<lpage>1589</lpage>.<pub-id pub-id-type="pmid">30442497</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="acr270045-cit-0041">
<string-name>
<surname>Cottu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tomelleri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Campochiaro</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Immune checkpoint inhibitors&#x02010;induced large vessel vasculitis: data from a multicenter study</article-title>. <source>Arthritis Rheumatol</source>
<year>2023</year>; <volume>75</volume> (suppl 9). <ext-link xlink:href="https://acrabstracts.org/abstract/immune-checkpoint-inhibitors-induced-large-vessel-vasculitis-data-from-a-multicenter-study/" ext-link-type="uri">https://acrabstracts.org/abstract/immune&#x02010;checkpoint&#x02010;inhibitors&#x02010;induced&#x02010;large&#x02010;vessel&#x02010;vasculitis&#x02010;data&#x02010;from&#x02010;a&#x02010;multicenter&#x02010;study/</ext-link>
</mixed-citation></ref><ref id="acr270045-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="acr270045-cit-0042">
<string-name>
<surname>Langford</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Cuthbertson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ytterberg</surname>
<given-names>SR</given-names>
</string-name>, et al; <article-title>Vasculitis Clinical Research Consortium. A randomized, double&#x02010;blind trial of abatacept (CTLA&#x02010;4Ig) for the treatment of giant cell arteritis</article-title>. <source>Arthritis Rheumatol</source>
<year>2017</year>;<volume>69</volume>(<issue>4</issue>):<fpage>837</fpage>&#x02013;<lpage>845</lpage>.<pub-id pub-id-type="pmid">28133925</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="acr270045-cit-0043">
<string-name>
<surname>Saraux</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Le Henaff</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dernis</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Abatacept in early polymyalgia rheumatica (ALORS): a proof&#x02010;of&#x02010;concept, randomised, placebo&#x02010;controlled, parallel&#x02010;group trial</article-title>. <source>Lancet Rheumatol</source>
<year>2023</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e728</fpage>&#x02013;<lpage>e735</lpage>.<pub-id pub-id-type="pmid">38251563</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="acr270045-cit-0044">
<string-name>
<surname>van der Geest</surname>
<given-names>KSM</given-names>
</string-name>, <string-name>
<surname>Sandovici</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rutgers</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Imaging in immune checkpoint inhibitor&#x02010;induced polymyalgia rheumatica</article-title>. <source>Ann Rheum Dis</source>
<year>2022</year>;<volume>81</volume>(<issue>10</issue>):<fpage>e210</fpage>&#x02013;<lpage>e211</lpage>.<pub-id pub-id-type="pmid">32241799</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="acr270045-cit-0045">
<string-name>
<surname>Martin de Fremont</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Belkhir</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Features of polymyalgia rheumatica&#x02010;like syndrome after immune checkpoint inhibitor therapy</article-title>. <source>Ann Rheum Dis</source>
<year>2022</year>;<volume>81</volume>(<issue>3</issue>):<elocation-id>e52</elocation-id>.<pub-id pub-id-type="pmid">32188691</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="acr270045-cit-0046">
<string-name>
<surname>Calabrese</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cappelli</surname>
<given-names>LC</given-names>
</string-name>. <article-title>Rheumatic immune&#x02010;related adverse events from cancer immunotherapy</article-title>. <source>Nat Rev Rheumatol</source>
<year>2018</year>;<volume>14</volume>(<issue>10</issue>):<fpage>569</fpage>&#x02013;<lpage>579</lpage>.<pub-id pub-id-type="pmid">30171203</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="acr270045-cit-0047">
<string-name>
<surname>Vermeulen</surname>
<given-names>OCB</given-names>
</string-name>, <string-name>
<surname>Brouwer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Slart</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Immune checkpoint inhibitor&#x02010;mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement</article-title>. <source>Rheumatology (Oxford)</source>
<year>2025</year>;<volume>64</volume>(<issue>2</issue>):<fpage>771</fpage>&#x02013;<lpage>779</lpage>.<pub-id pub-id-type="pmid">38335930</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="acr270045-cit-0048">
<string-name>
<surname>Cutolo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soldano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gotelli</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>CTLA4&#x02010;Ig treatment induces M1&#x02010;M2 shift in cultured monocyte&#x02010;derived macrophages from healthy subjects and rheumatoid arthritis patients</article-title>. <source>Arthritis Res Ther</source>
<year>2021</year>;<volume>23</volume>(<issue>1</issue>):<fpage>306</fpage>.<pub-id pub-id-type="pmid">34952630</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="acr270045-cit-0049">
<string-name>
<surname>Brizzolara</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Montagna</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Soldano</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Rapid interaction between CTLA4&#x02010;Ig (abatacept) and synovial macrophages from patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source>
<year>2013</year>;<volume>40</volume>(<issue>5</issue>):<fpage>738</fpage>&#x02013;<lpage>740</lpage>.<pub-id pub-id-type="pmid">23637380</pub-id>
</mixed-citation></ref><ref id="acr270045-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="acr270045-cit-0050">
<string-name>
<surname>Giusti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Camellino</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Saverino</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Zoledronate decreases CTLA&#x02010;4 in vivo and in vitro independently of its action on bone resorption</article-title>. <source>Bone</source>
<year>2020</year>;<volume>138</volume>:<elocation-id>115512</elocation-id>.<pub-id pub-id-type="pmid">32603908</pub-id>
</mixed-citation></ref></ref-list></back></article>